Table 4 Adverse and serious adverse events up to 6 months of observation
Most reported adverse events (AEs) n (%) | N = 99 |
|---|---|
Constipation | 21 (21.2) |
Insufficient effect | 6 (6.1) |
Lack of efficacy | 6 (6.1) |
Diarrhea | 5 (5.1) |
Injection site reaction | 2 (2.0) |
Serious adverse events (SAEs) n (%) | 12 (12.1) |
Anaphylactic shocka | 1 (1.0) |
Chest pain and arm pain left side | 1 (1.0) |
COVID-19 | 1 (1.0) |
Inpatient headache therapy | 2 (2.0) |
Kidney stone | 1 (1.0) |
Medication overuse headache needing withdrawal in hospital setting | 1 (1.0) |
Meningioma | 1 (1.0) |
Mycoplasma pneumonia | 1 (1.0) |
Right motor and sensory syndrome and migraine | 1 (1.0) |
Transitory ischemic attack | 1 (1.0) |
Urinary tract infection | 1 (1.0) |